CJC-1295 / Ipamorelin is a dual-peptide research formulation combining a growth hormone-releasing hormone (GHRH) analog with a synthetic growth hormone secretagogue. Because the two peptides interact with distinct receptor systems involved in growth hormone signaling, the combination has become an area of laboratory research involving pituitary signaling, receptor activity, and growth hormone-related biological pathways.

CJC-1295 research has explored its interaction with GHRH receptors and the signaling mechanisms associated with growth hormone secretion. Researchers have investigated GHRH-related pathways in experimental models involving pituitary activity and downstream insulin-like growth factor-1 (IGF-1) signaling.

Ipamorelin is a synthetic pentapeptide studied for its interaction with the growth hormone secretagogue receptor (GHS-R). Laboratory research has examined its receptor activity and relationship with signaling pathways involved in pulsatile growth hormone release and neuroendocrine communication.

Combining CJC-1295 and Ipamorelin allows researchers to investigate two complementary receptor pathways involved in growth hormone signaling within a single experimental formulation. This product contains 10mg CJC-1295 and 10mg Ipamorelin and is supplied in a nasal research format for controlled laboratory investigation involving GHRH, GHS-R, growth hormone, and related signaling pathways.